<?xml version='1.0' encoding='utf-8'?>
<ns0:TEI xmlns:ns0="http://www.tei-c.org/ns/1.0" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:space="preserve" xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd">
	<ns0:teiHeader xml:lang="en">
		<ns0:fileDesc>
			<ns0:titleStmt>
				<ns0:title level="a" type="main">2023 American College of Rheumatology (ACR) Guideline for the Screening and Monitoring of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Disease</ns0:title>
			</ns0:titleStmt>
			<ns0:publicationStmt>
				<ns0:publisher />
				<ns0:availability status="unknown"><ns0:licence /></ns0:availability>
			</ns0:publicationStmt>
			<ns0:sourceDesc>
				<ns0:biblStruct>
					<ns0:monogr>
						<ns0:imprint>
							<ns0:date />
						</ns0:imprint>
					</ns0:monogr>
					<ns0:idno type="MD5">AB9490E2CBB5C4579E5F0776547A04FE</ns0:idno>
					<ns0:note type="submission">ACR Board of Directors on 12 August 2023. These recommendations are included in a full manuscript, pending peer review, which was submitted for publication in Arthritis &amp; Rheumatology and Arthritis Care and Research.</ns0:note>
				</ns0:biblStruct>
			</ns0:sourceDesc>
		</ns0:fileDesc>
		</ns0:teiHeader>
	<ns0:text xml:lang="en">
		<ns0:body><ns0:div><ns0:head>Table 1. Summary of recommendations for screening of SARD-ILD</ns0:head></ns0:div><ns0:div><ns0:head>Summary of recommendations</ns0:head><ns0:p>For people with SARDs at increased risk of developing ILD, we conditionally recommend screening with PFTs.</ns0:p><ns0:p>For people with SARDs at increased risk of developing ILD, we conditionally recommend screening with HRCT of the chest.</ns0:p><ns0:p>For people with SARDs at increased risk of developing ILD, we conditionally recommend screening with HRCT chest and PFTs over PFTs alone.</ns0:p><ns0:p>For people with SARDs at increased risk of developing ILD, we conditionally recommend against screening with 6MWD.</ns0:p><ns0:p>For people with SARDs at increased risk of developing ILD, we conditionally recommend against screening with chest radiography.</ns0:p><ns0:p>For people with SARDs at increased risk of developing ILD, we conditionally recommend against screening with ambulatory desaturation testing.</ns0:p><ns0:p>For people with SARDs at increased risk of developing ILD, we conditionally recommend against screening with bronchoscopy.</ns0:p><ns0:p>For people with SARDs at increased risk of developing ILD, we strongly recommend against screening with surgical lung biopsy.</ns0:p></ns0:div><ns0:div><ns0:head>Table 2. Summary of Recommendations for Monitoring for ILD Progression</ns0:head></ns0:div><ns0:div><ns0:head>Summary of recommendations</ns0:head><ns0:p>For people with SARDs-ILD, we conditionally recommend monitoring with PFTs.</ns0:p><ns0:p>For people with SARDs-ILD, we conditionally recommend monitoring with HRCT chest.</ns0:p><ns0:p>For people with SARDs-ILD, we conditionally recommend monitoring with PFTs and HRCT chest over PFTs alone.</ns0:p><ns0:p>For people with SARDs-ILD, we conditionally recommend monitoring with ambulatory desaturation testing.</ns0:p><ns0:p>For people with SARDs-ILD, we conditionally recommend against monitoring with chest radiography.</ns0:p><ns0:p>For people with SARDs-ILD, we conditionally recommend against monitoring with 6MWD.</ns0:p><ns0:p>For people with SARDs-ILD, we conditionally recommend against monitoring with bronchoscopy.</ns0:p><ns0:p>For people with IIM-ILD and SSc-ILD, we suggest PFTs for monitoring every 3-6 months rather than either shorter or longer intervals, for the first year, then less frequently once stable.</ns0:p><ns0:p>For people with RA-ILD, SjD-ILD, and MCTD-ILD, we suggest PFTs for monitoring every 3-12 months rather than shorter or longer intervals, for the first year, then less frequently once stable.</ns0:p><ns0:p>For people with SARDs-ILD, we do not provide guidance about frequency of routine HRCT chest for monitoring ILD but suggest HRCT when clinically indicated.</ns0:p><ns0:p>For people with SARDs-ILD, we suggest assessment for ambulatory desaturation every 3-12 months rather than at shorter or longer intervals.</ns0:p></ns0:div></ns0:body><ns0:back>
			<ns0:div type="references">

				</ns0:div>
		</ns0:back>
	</ns0:text>
</ns0:TEI>